This was the stock's second consecutive day of losses.

Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

The rivalry between enterprise software makers Snowflake and Databricks intensified amid the emergence of generative ...

Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in ...

The EV maker's investors have to weigh what the CEO’s bid to gain control of the ChatGPT creator means for his time and their ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Thanks for following our live page today. Before we go, here's a round-up of the key developments today: Speculation continues to mount over when potential peace talks between Russia and Ukraine ...

it’s time to take stock of this quarter’s best and worst performers in the engineered components and systems industry, including Timken (NYSE:TKR) and its peers. New ABL facility marks ...